University Hospital of South Manchester NHS trust
Manchester, M23 9LT, United Kingdom
NCT Number: NCT01842243
Despite considerable effort the optimal site to place a pacemaker lead at the time of pacemaker implant remains unclear. Historically pacemaker leads have always been inserted at the bottom (apex) of the heart. It is suggested that a lead placed at the apex is associated with an increase in heart rhythm problems and also heart failure (impaired pumping function). The top of the ventricle (septum) has been investigated as an alternative site and is now routinely used by some centres. Previous estimation of the hearts pumping function (ejection fraction) has been limited to the use of echo (sound waves). Echo is not sensitive enough to detect small changes in the ejection fraction reliably (measure of pumping function of heart). The gold standard for measurement of ejection fraction is MRI (using magnets). Previous pacemakers have not been compatible with MRI scans. The latest generation of pacemakers are now able to be safely scanned within an MRI scanner. This allows a much more accurate estimation of the effects of a pacemaker on the ejection fraction which has not yet been studied.
The investigators plan to study those patients undergoing a pacemaker implant and ablation procedure as part of their standard care.
Individuals will have an exercise test, blood test used to measure biomarkers and fill in a symptom questionnaire.
Individuals will have a Cardiac MR compatible pacemaker fitted and 2 ventricular leads will be inserted, one apically and one septally. Only one lead will be used at any given time. Individuals will then undergo their planned AV node ablation.
Following this they will have a cardiac MR scan. Further MRI scans will be performed at 9 and 18 month intervals, as will symptom questionnaires, blood tests (BNP) to determine heart muscle strain, exercise testing and echocardiograms.
The hypothesis is that a lead placed on the septum will produce superior cardiac performance over the short and long term.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Manchester, M23 9LT, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pacemaker set to pace at right ventricular apex initially.
Pacemaker set to pace at right ventricular septum initially.
MR conditional Pacemaker implanted in all study patients
Other names: MR conditional Pacemaker
Time frame: 18 months
Comparison of % change in Left and Right Ventricular Ejection Fractions between apical and septal pacing groups as measured on MRI.
Time frame: 18 months
Blood Sampling
Time frame: 18 months
Time frame: 18 months
Time frame: 18 months
Time frame: 18 months
Time frame: 18 months
Blood sampling
Time frame: 18 months
Blood sampling
Time frame: 18 months
Blood sampling
Time frame: 18 months
Blood sampling
Time frame: 18 months
Blood sampling
Time frame: 18 months
Blood sampling
Time frame: 18 months
Blood sampling
Manchester University NHS Foundation Trust
Other Gov
Multiparametric CMR Assessment of Apical Versus Septal Pacing Study
Acronym: MAPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07512310
Cardiovascular Diseases, Heart Diseases
Essen, Germany
View Trial DetailsNCT00526162
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Bonn, Germany
View Trial DetailsNCT02497950
Cardiovascular Disease, Cardiovascular Diseases
Vienna, Austria
View Trial DetailsNCT06817044
Cardiotoxicity, Cardiovascular Diseases
London, United Kingdom
View Trial Details